|Dr. Patrick Amstutz Ph.D.||Co-Founder, CEO, Member of Management Board & Director||666k||N/A||1975|
|Dr. Michael Tobias Stumpp Ph.D.||Co-Founder, Exec. VP of Projects & Member of Management Board||N/A||N/A||1972|
|Mr. Andreas Emmenegger E.M.B.A.||Advisor||N/A||N/A||1966|
|Mr. Alexander Zurcher||COO & Member of Management Board||N/A||N/A||N/A|
|Dr. Nicolas Leupin M.B.A., Ph.D., M.D., MBA||Chief Medical Officer & Member of Management Board||N/A||N/A||1973|
|Ms. Renate Gloggner||Exec. VP of People & Community and Member of Management Board||N/A||N/A||N/A|
|Mr. Daniel Steiner Ph.D.||Sr. VP of Research||N/A||N/A||N/A|
|Mr. Seth D. Lewis||Sr. VP of Investor Relations, Communications & Strategy||N/A||N/A||N/A|
|Mr. Michael Pitzner||Gen. Counsel, Compliance Officer & Sr. VP of Legal||N/A||N/A||N/A|
|Mr. Thomas Schwerzmann||VP of HR||N/A||N/A||N/A|
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Molecular Partners AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.